Is Galleri the future of cancer treatment? It's not that simple. The new research from the company, while promising, isn't ...

Jack Welter didn’t feel sick when he agreed to take a new blood test that looks for multiple types of cancer. But, approaching 60, he thought it couldn’t hurt. To his surprise, the test came back ...

A pioneering blood test designed to screen for more than 50 types of cancer, currently being evaluated by the NHS, has correctly identified the disease in nearly two-thirds of cases it flagged. The ...

If you could take a simple blood test that could detect multiple types of cancer while they’re still in an early and treatable stage, would you? For many, the answer would be a resounding yes.

The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may attract risk tolerant investors now.

Multicancer blood tests have for years been hyped as a potential breakthrough in early cancer detection. But with news that one of the big names in the field, the Galleri test, failed to meet its ...

Source: Getty Images The NHS-Galleri trial could potentially lead to widespread adoption of the Galleri MCED test in NHS clinics, but some experts believe the trial’s primary endpoint is inappropriate ...

HealthDay News — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of ...

MENLO PARK, Calif. and LONDON, Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced topline ...

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket ...